Skip to content

GlObal Secondary Prevention strategiEs to Limit Event Recurrence After Myocardial Infarction. GOSPEL Study

GlObal Secondary Prevention strategiEs to Limit Event Recurrence After Myocardial Infarction. GOSPEL Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00421876
Enrollment
3200
Registered
2007-01-15
Start date
2000-12-31
Completion date
2005-12-31
Last updated
2021-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Keywords

cardiac rehabilitation, lifestyle management, risk factor management, myocardial infarction, randomized trials

Brief summary

Cardiac rehabilitation programmes are a proven treatment for individuals with recent myocardial infarction, resulting in reduced morbidity and mortality compared to usual care. Unfortunately, following completion of a cardiac rehabilitation programme, risk factors and lifestyle behaviours may deteriorate. The GOSPEL study investigates the benefits of a programme of continued educational and behavioural intervention to achieve optimal long-term secondary prevention goals.

Detailed description

Study partially sponsored by Società Prodotti Antibiotici

Interventions

BEHAVIORALmultifactorial continued educational - behavioural programme

Sponsors

Heart Care Foundation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Recent myocardial infarction (within 3 months after the index event) * Standard rehabilitation program of 3-6 weeks performed * Informed consent (obtained before any study specific procedure)

Exclusion criteria

* Age \> 75 years * Any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or be associated with poor adherence to the protocol; * Presence of any non-cardiac disease (e.g. cancer) that is likely to significantly shorten life expectancy

Design outcomes

Primary

MeasureTime frame
cardiovascular mortality
non fatal re-MI
angina requiring hospitalization
urgent revascularization procedures
hospitalization for heart failure
non fatal stroke

Countries

Italy, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026